Progress on the pathogenesis and treatment of transplantation-associated thrombotic microangiopathy
10.3760/cma.j.issn.1673-4408.2025.06.009
- VernacularTitle:移植相关血栓性微血管病发病机制及治疗研究进展
- Author:
Zhiqi ZHANG
1
;
Ruolan XIONG
;
Shuiyan WU
;
Shaoyan HU
Author Information
1. 苏州大学附属儿童医院血液科 215000
- Keywords:
Transplantation-associated thrombotic microangiopathy;
Pathogenesis;
Treatment
- From:
International Journal of Pediatrics
2025;52(6):400-404
- CountryChina
- Language:Chinese
-
Abstract:
Transplantation-associated thrombotic microangiopathy（TA-TMA）is one of the severe complications after hematopoietic stem cell transplantation，and its specific pathogenesis has not yet been fully elucidated. In recent years，with in-depth research on TA-TMA，its pathogenesis has been gradually elucidated. It primarily involves multiple factors，including endothelial injury，aberrant activation of the complement system，and oxidative stress.Regarding treatment，in addition to conventional supportive therapy and etiology-directed management，various targeted therapies have emerged，including drugs like Eculizumab，recombinant thrombomodulin，defibrotide，and N-acetylcysteine.This article aims to systematically review the current research achievements and latest progress on the pathogenesis and treatment methods of TA-TMA，to provide references for the early prevention and treatment of TA-TMA.
